nach oben

Current Allergy and Asthma Reports

Erschienen in:

01.08.2014 | ANAPHYLAXIS AND DRUG ALLERGY (DA KHAN AND M CASTELLS, SECTION EDITORS)

Diagnostic Tools for Hypersensitivity to Platinum Drugs and Taxanes: Skin Testing, Specific IgE, and Mast Cell/Basophil Mediators

verfasst von: Joana Caiado, Matthieu Picard

Erschienen in: Current Allergy and Asthma Reports | Ausgabe 8/2014

Einloggen, um Zugang zu erhalten

Abstract

Hypersensitivity reactions (HSRs) to platinum drugs and taxanes are increasing in cancer patients, and rapid drug desensitization has emerged as a safe and effective method to reintroduce these drugs in reactive patients. Optimal management of patients presenting HSRs to chemotherapy depends on the use of various diagnostic tools, which include measurement of mast cell/basophil mediator release following a HSR and skin testing. Serum tryptase should be measured in patients presenting chemotherapy HSRs, and its elevation would support mast cell/basophil activation. Skin testing to platinum drugs has a high sensitivity and specificity and is critical to guide the management of platinum-reactive patients. Taxane skin testing is also emerging as a useful diagnostic and risk stratification tool in the evaluation of patients with HSRs to taxanes. Platinum sIgE assays have been recently developed and can be helpful in combination with skin testing or as an alternative when skin testing is not available.

Mezzano V, Giavina-Bianchi P, Picard M, Caiado J, Castells M. Drug desensitization in the management of hypersensitivity reactions to monoclonal antibodies and chemotherapy. BioDrugs. 2014;28(2):133–44.PubMed

Castells MC, Tennant NM, Sloane DE, Hsu FI, Barrett NA, Hong DI, et al. Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases. J Allergy Clin Immunol. 2008;122(3):574–80.PubMed

3.••

Patil SU, Long AA, Ling M, Wilson MT, Hesterberg P, Wong JT, et al. A protocol for risk stratification of patients with carboplatin-induced hypersensitivity reactions. J Allergy Clin Immunol. 2012;129(2):443–7. Risk stratification of patients with carboplatin-induced hypersensitivity reaction trough clinical presentation and skin testing.PubMed

4.•

Madrigal-Burgaleta R, Berges-Gimeno MP, Angel-Pereira D, Ferreiro-Monteagudo R, Guillen-Ponce C, Pueyo C, et al. Hypersensitivity and desensitization to antineoplastic agents: outcomes of 189 procedures with a new short protocol and novel diagnostic tools assessment. Allergy. 2013;68(7):853–61. Outcomes of a desensitization to chemotherapeutics in a large cohort of patients; assessment of the value of oxaliplatin-specific IgE.PubMed

Chatelut E. Pharmacology of platinum compounds: differences between the three molecules and factors of interpatient variability. Bull Cancer. 2011;98(11):1253–61.PubMed

Haugnes HS, Bosl GJ, Boer H, Gietema JA, Brydoy M, Oldenburg J, et al. Long-term and late effects of germ cell testicular cancer treatment and implications for follow-up. J Clin Oncol Off J Am Soc Clin Oncol. 2012;30(30):3752–63.

Geiger JL, Lazim AF, Walsh FJ, Foote RL, Moore EJ, Okuno SH, et al. Adjuvant chemoradiation therapy with high-dose versus weekly cisplatin for resected, locally-advanced HPV/p16-positive and negative head and neck squamous cell carcinoma. Oral Oncol. 2014;50(4):311–8.

Sakaeda T, Kadoyama K, Okuno Y. Adverse event profiles of platinum agents: data mining of the public version of the FDA adverse event reporting system, AERS, and reproducibility of clinical observations. Int J Med Sci. 2011;8(6):487–91.PubMedCentralPubMed

Sprauten M, Darrah TH, Peterson DR, Campbell ME, Hannigan RE, Cvancarova M, et al. Impact of long-term serum platinum concentrations on neuro- and ototoxicity in Cisplatin-treated survivors of testicular cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2012;30(3):300–7.

10.

Andre T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350(23):2343–51.PubMed

11.

Navo M, Kunthur A, Badell ML, Coffer 2nd LW, Markman M, Brown J, et al. Evaluation of the incidence of carboplatin hypersensitivity reactions in cancer patients. Gynecol Oncol. 2006;103(2):608–13.PubMed

12.

Liu A, Fanning L, Chong H, Fernandez J, Sloane D, Sancho-Serra M, et al. Desensitization regimens for drug allergy: state of the art in the 21st century. Clin Exp Allergy J Br Soc Allergy Clin Immunol. 2011;41(12):1679–89.

13.

Koren C, Yerushalmi R, Katz A, Malik H, Sulkes A, Fenig E. Hypersensitivity reaction to cisplatin during chemoradiation therapy for gynecologic malignancy. Am J Clin Oncol. 2002;25(6):625–6.PubMed

14.

Makrilia N, Syrigou E, Kaklamanos I, Manolopoulos L, Saif MW. Hypersensitivity reactions associated with platinum antineoplastic agents: a systematic review. Metal-Based Drugs. 2010;2010.

15.

Park SJ, Lee KY, Park WS, Min SY. Clinical outcomes of reintroducing oxaliplatin to patients with colorectal cancer after mild hypersensitivity reactions. Oncology. 2013;85(6):323–7.PubMed

16.

Parel M, Ranchon F, Nosbaum A, You B, Vantard N, Schwiertz V, et al. Hypersensitivity to oxaliplatin: clinical features and risk factors. BMC Pharmacol Toxicol. 2014;15:1.PubMedCentralPubMed

17.

Polyzos A, Tsavaris N, Gogas H, Souglakos J, Vambakas L, Vardakas N, et al. Clinical features of hypersensitivity reactions to oxaliplatin: a 10-year experience. Oncology. 2009;76(1):36–41.PubMed

18.

Kim MY, Kang SY, Lee SY, Yang MS, Kim MH, Song WJ, et al. Hypersensitivity reactions to oxaliplatin: clinical features and risk factors in Koreans. Asian Pac J Cancer Prev APJCP. 2012;13(4):1209–15.

19.

Kim BH, Bradley T, Tai J, Budman DR. Hypersensitivity to oxaliplatin: an investigation of incidence and risk factors, and literature review. Oncology. 2009;76(4):231–8.PubMed

20.

Lenz HJ. Management and preparedness for infusion and hypersensitivity reactions. Oncologist. 2007;12(5):601–9.PubMed

21.

Markman M, Kennedy A, Webster K, Elson P, Peterson G, Kulp B, et al. Clinical features of hypersensitivity reactions to carboplatin. J Clin Oncol Off J Am Soc Clin Oncol. 1999;17(4):1141.

22.

Zanotti KM, Rybicki LA, Kennedy AW, Belinson JL, Webster KD, Kulp B, et al. Carboplatin skin testing: a skin-testing protocol for predicting hypersensitivity to carboplatin chemotherapy. J Clin Oncol Off J Am Soc Clin Oncol. 2001;19(12):3126–9.

23.

Markman M, Zanotti K, Peterson G, Kulp B, Webster K, Belinson J. Expanded experience with an intradermal skin test to predict for the presence or absence of carboplatin hypersensitivity. J Clin Oncol Off J Am Soc Clin Oncol. 2003;21(24):4611–4.

24.

Lee CW, Matulonis UA, Castells MC. Carboplatin hypersensitivity: a 6-h 12-step protocol effective in 35 desensitizations in patients with gynecological malignancies and mast cell/IgE-mediated reactions. Gynecol Oncol. 2004;95(2):370–6.PubMed

25.

Lee CW, Matulonis UA, Castells MC. Rapid inpatient/outpatient desensitization for chemotherapy hypersensitivity: standard protocol effective in 57 patients for 255 courses. Gynecol Oncol. 2005;99(2):393–9.PubMed

26.

Confino-Cohen R, Fishman A, Altaras M, Goldberg A. Successful carboplatin desensitization in patients with proven carboplatin allergy. Cancer. 2005;104(3):640–3.PubMed

27.

Hesterberg PE, Banerji A, Oren E, Penson RT, Krasner CN, Seiden MV, et al. Risk stratification for desensitization of patients with carboplatin hypersensitivity: clinical presentation and management. J Allergy Clin Immunol. 2009;123(6):1262–7 e1.PubMed

28.

Garufi C, Cristaudo A, Vanni B, Bria E, Aschelter AM, Santucci B, et al. Skin testing and hypersensitivity reactions to oxaliplatin. Ann Oncol Off J Eur Soc Med Oncol ESMO. 2003;14(3):497–8.

29.

Herrero T, Tornero P, Infante S, Fuentes V, Sanchez MN, De Barrio M, et al. Diagnosis and management of hypersensitivity reactions caused by oxaliplatin. J Investig Allergol Clin Immunol. 2006;16(5):327–30.PubMed

30.

Pagani M, Bonadonna P, Senna GE, Antico A. Standardization of skin tests for diagnosis and prevention of hypersensitivity reactions to oxaliplatin. Int Arch Allergy Immunol. 2008;145(1):54–7.PubMed

31.

Pagani M, Bonadonna P. Skin test protocol for the prevention of hypersensitivity reactions to oxaliplatin. Anticancer Res. 2014;34(1):537–40.PubMed

32.

Wong JT, Ling M, Patil S, Banerji A, Long A. Oxaliplatin hypersensitivity: evaluation, implications of skin testing, and desensitization. J Allergy Clin Immunol Pract. 2014;2(1):40–5.PubMed

33.

Leguy-Seguin V, Jolimoy G, Coudert B, Pernot C, Dalac S, Vabres P, et al. Diagnostic and predictive value of skin testing in platinum salt hypersensitivity. J Allergy Clin Immunol. 2007;119(3):726–30.PubMed

34.••

Caiado J, Venemalm L, Pereira-Santos MC, Costa L, Barbosa MP, Castells M. Carboplatin-, oxaliplatin-, and cisplatin-specific IgE: cross-reactivity and value in the diagnosis of carboplatin and oxaliplatin allergy. J Allergy Clin Immunol Pract. 2013;1(5):494–500. Assessment of the value of platinum-specific IgE in the diagnosis and evaluating the cross-reactivity between different platinum drugs in 24 patients and 17 controls.PubMed

35.

Pagani M, Venemalm L, Bonnadona P, Vescovi PP, Botelho C, Cernadas JR. An experimental biological test to diagnose hypersensitivity reactions to carboplatin: new horizons for an old problem. Jpn J Clin Oncol. 2012;42(4):347–50.PubMed

36.

Tournigand C, Maindrault-Goebel F, Louvet C, de Gramont A, Krulik M. Severe anaphylactic reactions to oxaliplatin. Eur J Cancer. 1998;34(8):1297–8.PubMed

37.

Medioni J, Coulon MA, Morere JF, Hennebelle F, Piperno-Neumann S, Breau JL. Anaphylaxis after oxaliplatin. Ann Oncol Off J Eur Soc Med Oncol ESMO. 1999;10(5):610.

38.

Wang JH, King TM, Chang MC, Hsu CW. Oxaliplatin-induced severe anaphylactic reactions in metastatic colorectal cancer: case series analysis. World J Gastroenterol WJG. 2012;18(38):5427–33.

39.

Gastaminza G, de la Borbolla JM, Goikoetxea MJ, Escudero R, Anton J, Espinos J, et al. A new rapid desensitization protocol for chemotherapy agents. J Investig Allergol Clin Immunol. 2011;21(2):108–12.PubMed

40.

Madrigal-Burgaleta R, Berges-Gimeno MP, Angel-Pereira D, Guillen-Ponce C, Sanz ML, Alvarez-Cuesta E. Desensitizing oxaliplatin-induced fever: a case report. J Investig Allergol Clin Immunol. 2013;23(6):435–6.PubMed

41.

Santini D, Tonini G, Salerno A, Vincenzi B, Patti G, Battistoni F, et al. Idiosyncratic reaction after oxaliplatin infusion. Ann Oncol Off J Eur Soc Med Oncol ESMO. 2001;12(1):132–3.

42.

Ulrich-Pur H, Penz M, Fiebiger WC, Schull B, Kornek GV, Scheithauer W, et al. Oxaliplatin-induced fever and release of IL-6. Oncology. 2000;59(3):187–9.PubMed

43.

Khan DA, Solensky R. Drug allergy. J Allergy Clin Immunol. 2010;125(2 Suppl 2):S126–37.PubMed

44.

Schwartz JR, Bandera C, Bradley A, Brard L, Legare R, Granai CO, et al. Does the platinum-free interval predict the incidence or severity of hypersensitivity reactions to carboplatin? The experience from Women and Infants’ Hospital. Gynecol Oncol. 2007;105(1):81–3.PubMed

45.

Sliesoraitis S, Chikhale PJ. Carboplatin hypersensitivity. Int J Gynecol Cancer Off J Int Gynecol Cancer Soc. 2005;15(1):13–8.

46.

Gadducci A, Tana R, Teti G, Zanca G, Fanucchi A, Genazzani AR. Analysis of the pattern of hypersensitivity reactions in patients receiving carboplatin retreatment for recurrent ovarian cancer. Int J Gynecol Cancer Off J Int Gynecol Cancer Soc. 2008;18(4):615–20.

47.

Moon DH, Lee JM, Noonan AM, Annunziata CM, Minasian L, Houston N, et al. Deleterious BRCA1/2 mutation is an independent risk factor for carboplatin hypersensitivity reactions. Br J Cancer. 2013;109(4):1072–8.PubMedCentralPubMed

48.

Maindrault-Goebel F, Andre T, Tournigand C, Louvet C, Perez-Staub N, Zeghib N, et al. Allergic-type reactions to oxaliplatin: retrospective analysis of 42 patients. Eur J Cancer. 2005;41(15):2262–7.PubMed

49.

Siu SW, Chan RT, Au GK. Hypersensitivity reactions to oxaliplatin: experience in a single institute. Ann Oncol Off J Eur Soc Med Oncol ESMO. 2006;17(2):259–61.

50.

Picard M, Matulonis UA, Castells M. Chemotherapy hypersensitivity reactions in ovarian cancer. J Natl Compr Cancer Netw. 2014;12(3):389–402.

51.

Taxol prescribing information 2014 [January 13, 2014]. Available from: http://packageinserts.bms.com/pi/pi_taxol.pdf.

52.

Taxotere prescribing information 2013 [December 24, 2013]. Available from: http://products.sanofi.us/Taxotere/taxotere.html.

53.

Abraxane prescribing information 2014 [January 3, 2014]. Available from: http://abraxane.com/downloads/Abraxane_PrescribingInformation.pdf.

54.

Cabazitaxel prescribing information 2014 [January 12, 2014]. Available from: http://products.sanofi.us/jevtana/jevtana.html.

55.

Weiss RB, Donehower RC, Wiernik PH, Ohnuma T, Gralla RJ, Trump DL, et al. Hypersensitivity reactions from taxol. J Clin Oncol. 1990;8(7):1263–8.PubMed

56.

Markman M, Kennedy A, Webster K, Kulp B, Peterson G, Belinson J. Paclitaxel-associated hypersensitivity reactions: experience of the gynecologic oncology program of the Cleveland Clinic Cancer Center. J Clin Oncol. 2000;18(1):102–5.PubMed

57.

A fatal anaphylactic reaction to paclitaxel is described, which was preceded by a possible delayed reaction to the initial infusion. Allergy Asthma Proc. 2011;32(1):79.

58.

Picard M, Pur L, Caiado J, Galvao V, Giavina-Bianchi P, Castells M. Added value of skin testing in hypersensitivity reactions to taxanes [Abstract]. J Allergy Clin Immunol. 2014;133(2):AB152.

59.

Wani MC, Taylor HL, Wall ME, Coggon P, McPhail AT. Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc. 1971;93(9):2325–7.PubMed

60.

Exposito O, Bonfill M, Moyano E, Onrubia M, Mirjalili MH, Cusido RM, et al. Biotechnological production of taxol and related taxoids: current state and prospects. Anticancer Agents Med Chem. 2009;9(1):109–21.PubMed

61.

Gennari A, Salvadori B, Tognoni A, Conte PF. Rapid intravenous premedication with dexamethasone prevents hypersensitivity reactions to paclitaxel. Ann Oncol. 1996;7(9):978–9.PubMed

62.

Bookman MA, Kloth DD, Kover PE, Smolinski S, Ozols RF. Short-course intravenous prophylaxis for paclitaxel-related hypersensitivity reactions. Ann Oncol. 1997;8(6):611–4.PubMed

63.

Markman M, Kennedy A, Webster K, Peterson G, Kulp B, Belinson J. Simplified regimen for the prevention of paclitaxel-associated hypersensitivity reactions. J Clin Oncol. 1997;15(12):3517.PubMed

64.

Kwon JS, Elit L, Finn M, Hirte H, Mazurka J, Moens F, et al. A comparison of two prophylactic regimens for hypersensitivity reactions to paclitaxel. Gynecol Oncol. 2002;84(3):420–5.PubMed

65.

Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD, Gianni L, Myles J, van der Burg ME, et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J Clin Oncol. 1994;12(12):2654–66.PubMed

66.

Micha JP, Rettenmaier MA, Dillman R, Fraser P, Birk C, Brown JV. Single-dose dexamethasone paclitaxel premedication. Gynecol Oncol. 1998;69(2):122–4.PubMed

67.

Cormio G, Di Vagno G, Melilli GA, Cazzolla A, Di Gesu G, Carriero C, et al. Hypersensitivity reactions in ovarian cancer patients receiving paclitaxel. J Chemother. 1999;11(5):407–9.PubMed

68.

Schrijvers D, Wanders J, Dirix L, Prove A, Vonck I, van Oosterom A, et al. Coping with toxicities of docetaxel (Taxotere). Ann Oncol. 1993;4(7):610–1.PubMed

69.

Francis PA, Rigas JR, Kris MG, Pisters KM, Orazem JP, Woolley KJ, et al. Phase II trial of docetaxel in patients with stage III and IV non-small-cell lung cancer. J Clin Oncol. 1994;12(6):1232–7.PubMed

70.

Semb KA, Aamdal S, Oian P. Capillary protein leak syndrome appears to explain fluid retention in cancer patients who receive docetaxel treatment. J Clin Oncol. 1998;16(10):3426–32.PubMed

71.

Cortes JE, Pazdur R. Docetaxel. J Clin Oncol. 1995;13(10):2643–55.PubMed

72.

Vasey PA, Jayson GC, Gordon A, Gabra H, Coleman R, Atkinson R, et al. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst. 2004;96(22):1682–91.PubMed

73.

Syrigou E, Dannos I, Kotteas E, Makrilia N, Tourkantonis I, Dilana K, et al. Hypersensitivity reactions to docetaxel: retrospective evaluation and development of a desensitization protocol. Int Arch Allergy Immunol. 2011;156(3):320–4.PubMed

74.

Ma P, Mumper RJ. Paclitaxel nano-delivery systems: a comprehensive review. J Nanomedicine Nanotechnol. 2013;4(2):1000164.

75.

Gradishar WJ, Tjulandin S, Davidson N, Shaw H, Desai N, Bhar P, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol. 2005;23(31):7794–803.PubMed

76.

Yamamoto Y, Kawano I, Iwase H. Nab-paclitaxel for the treatment of breast cancer: efficacy, safety, and approval. Onco Targets Ther. 2011;4:123–36.PubMedCentralPubMed

77.

Micha JP, Goldstein BH, Birk CL, Rettenmaier MA, Brown 3rd JV. Abraxane in the treatment of ovarian cancer: the absence of hypersensitivity reactions. Gynecol Oncol. 2006;100(2):437–8.PubMed

78.

Fader AN, Rose PG. Abraxane for the treatment of gynecologic cancer patients with severe hypersensitivity reactions to paclitaxel. Int J Gynecol Cancer. 2009;19(7):1281–3.PubMed

79.

Galsky MD, Dritselis A, Kirkpatrick P, Oh WK. Cabazitaxel. Nat Rev Drug Discov. 2010;9(9):677–8.PubMed

80.

de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376(9747):1147–54.PubMed

81.

Bracarda S, Gernone A, Gasparro D, Marchetti P, Gianni L, Bortolus R, et al. Real-world cabazitaxel safety: the Italian early-access program in metastatic castration-resistant prostate cancer. Future Oncol. 2013.

82.

Pivot X, Koralewski P, Hidalgo JL, Chan A, Goncalves A, Schwartsmann G, et al. A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients. Ann Oncol. 2008;19(9):1547–52.PubMed

83.

Dizon DS, Sabbatini PJ, Aghajanian C, Hensley ML, Spriggs DR. Analysis of patients with epithelial ovarian cancer or fallopian tube carcinoma retreated with cisplatin after the development of a carboplatin allergy. Gynecol Oncol. 2002;84(3):378–82.PubMed

84.

Zweizig S, Roman LD, Muderspach LI. Death from anaphylaxis to cisplatin: a case report. Gynecol Oncol. 1994;53(1):121–2.PubMed

85.

Elligers KT, Davies M, Sanchis D, Ferencz T, Saif MW. Rechallenge with cisplatin in a patient with pancreatic cancer who developed a hypersensitivity reaction to oxaliplatin. Is skin test useful in this setting? JOP J Pancreas. 2008;9(2):197–202.

86.

Enrique E, Malek T, Castello JV, de Mateo JA. Usefulness of skin testing with platinum salts to demonstrate lack of cross-reactivity between carboplatin and cisplatin. Ann Allergy Asthma Immunol Off Publ Am Coll Allergy Asthma Immunol. 2008;100(1):86.

87.

Syrigou E, Makrilia N, Vassias A, Nikolaidis I, Xyla V, Manolopoulos L, et al. Administration of cisplatin in three patients with carboplatin hypersensitivity: is skin testing useful? Anti-Cancer Drugs. 2010;21(3):333–8.PubMed

88.

Brockow K, Romano A, Blanca M, Ring J, Pichler W, Demoly P. General considerations for skin test procedures in the diagnosis of drug hypersensitivity. Allergy. 2002;57(1):45–51.PubMed

89.

Limsuwan T, Castells MC. Outcomes and safety of rapid desensitization for chemotherapy hypersensitivity. Expert Opin Drug Saf. 2010;9(1):39–53.PubMed

90.

Brockow K, Garvey LH, Aberer W, Atanaskovic-Markovic M, Barbaud A, Bilo MB, et al. Skin test concentrations for systemically administered drugs—an ENDA/EAACI Drug Allergy Interest Group position paper. Allergy. 2013;68(6):702–12.PubMed

91.

Prieto Garcia A, Pineda de la Losa F. Immunoglobulin E-mediated severe anaphylaxis to paclitaxel. J Investig Allergol Clin Immunol. 2010;20(2):170–1.PubMed

92.

Messaad D, Sablayrolles P, Pujol JL, Demoly P. Successful docetaxel tolerance induction. Allergy. 2003;58(12):1320–1.PubMed

93.

Zambonino MA, Corzo JL, Munoz C, Requena G, Ariza A, Mayorga C, et al. Diagnostic evaluation of hypersensitivity reactions to beta-lactam antibiotics in a large population of children. Pediatr Allergy Immunol Off Publ Eur Soc Pediatr Allergy Immunol. 2014;25(1):80–7.

94.

Garcia Nunez I, Barasona Villarejo MJ, Algaba Marmol MA, Moreno Aguilar C, Guerra Pasadas F. Diagnosis of patients with immediate hypersensitivity to beta-lactams using retest. J Investig Allergol Clin Immunol. 2012;22(1):41–7.PubMed

95.

Silva R, Cruz L, Botelho C, Castro E, Cadinha S, Castel-Branco MG, et al. Immediate hypersensitivity to penicillins with negative skin tests—the value of specific IgE. Eur Ann Allergy Clin Immunol. 2009;41(4):117–9.PubMed

96.

Fernandez J, Torres MJ, Campos J, Arribas-Poves F, Blanca M, Group DA-D. Prospective, multicenter clinical trial to validate new products for skin tests in the diagnosis of allergy to penicillin. J Investig Allergol Clin Immunol. 2013;23(6):398–408.PubMed

97.

Fontaine C, Mayorga C, Bousquet PJ, Arnoux B, Torres MJ, Blanca M, et al. Relevance of the determination of serum-specific IgE antibodies in the diagnosis of immediate beta-lactam allergy. Allergy. 2007;62(1):47–52.PubMed

98.

Cromwell O, Pepys J, Parish WE, Hughes EG. Specific IgE antibodies to platinum salts in sensitized workers. Clin Allergy. 1979;9(2):109–17.PubMed

99.

Vanhaelen M, Duchateau J, Vanhaelen-Fastre R, Jaziri M. Taxanes in Taxus baccata pollen: cardiotoxicity and/or allergenicity? Planta Med. 2002;68(1):36–40.PubMed

100.

Stone SF, Cotterell C, Isbister GK, Holdgate A, Brown SG, Emergency Department Anaphylaxis Investigators. Elevated serum cytokines during human anaphylaxis: identification of potential mediators of acute allergic reactions. J Allergy Clin Immunol. 2009;124(4):786–92 e4.PubMed

101.

Brown SG. Clinical features and severity grading of anaphylaxis. J Allergy Clin Immunol. 2004;114(2):371–6.PubMed

102.

Brown SG, Blackman KE, Heddle RJ. Can serum mast cell tryptase help diagnose anaphylaxis? Emerg Med Australasia EMA. 2004;16(2):120–4.

103.

Brown SG, Stone SF, Fatovich DM, Burrows SA, Holdgate A, Celenza A, et al. Anaphylaxis: clinical patterns, mediator release, and severity. J Allergy Clin Immunol. 2013;132(5):1141–9 e5.PubMed

104.

Picard M, Giavina-Bianchi P, Mezzano V, Castells M. Expanding spectrum of mast cell activation disorders: monoclonal and idiopathic mast cell activation syndromes. Clin Ther. 2013;35(5):548–62.PubMed

105.

Valent P, Akin C, Arock M, Brockow K, Butterfield JH, Carter MC, et al. Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal. Int Arch Allergy Immunol. 2012;157(3):215–25.PubMedCentralPubMed

106.

Abajian M, Mlynek A, Maurer M. Physical urticaria. Curr Allergy Asthma Rep. 2012;12(4):281–7.PubMed

107.

Medic N, Desai A, Komarow H, Burch LH, Bandara G, Beaven MA, et al. Examination of the role of TRPM8 in human mast cell activation and its relevance to the etiology of cold-induced urticaria. Cell Calcium. 2011;50(5):473–80.PubMedCentralPubMed

108.

Douaiher J, Succar J, Lancerotto L, Gurish MF, Orgill DP, Hamilton MJ, et al. Development of mast cells and importance of their tryptase and chymase serine proteases in inflammation and wound healing. Adv Immunol. 2014;122:211–52.PubMedCentralPubMed

109.

Brown SG. Cardiovascular aspects of anaphylaxis: implications for treatment and diagnosis. Curr Opin Allergy Clin Immunol. 2005;5(4):359–64.PubMed

110.

Sala-Cunill A, Cardona V, Labrador-Horrillo M, Luengo O, Esteso O, Garriga T, et al. Usefulness and limitations of sequential serum tryptase for the diagnosis of anaphylaxis in 102 patients. Int Arch Allergy Immunol. 2013;160(2):192–9.PubMed

111.

Cardet JC, Castells MC, Hamilton MJ. Immunology and clinical manifestations of non-clonal mast cell activation syndrome. Curr Allergy Asthma Rep. 2013;13(1):10–8.PubMedCentralPubMed

112.

Hamilton RG. Clinical laboratory assessment of immediate-type hypersensitivity. J Allergy Clin Immunol. 2010;125(2 Suppl 2):S284–96.PubMed

113.

Payne V, Kam PC. Mast cell tryptase: a review of its physiology and clinical significance. Anaesthesia. 2004;59(7):695–703.PubMed

114.

Michalska-Krzanowska G. Tryptase in diagnosing adverse suspected anaphylactic reaction. Adv Clin Exp Med Off Organ Wroclaw Med Univ. 2012;21(3):403–8.

115.

Schwartz LB, Yunginger JW, Miller J, Bokhari R, Dull D. Time course of appearance and disappearance of human mast cell tryptase in the circulation after anaphylaxis. J Clin Invest. 1989;83(5):1551–5.PubMedCentralPubMed

116.

Vadas P, Perelman B, Liss G. Platelet-activating factor, histamine, and tryptase levels in human anaphylaxis. J Allergy Clin Immunol. 2013;131(1):144–9.PubMed

117.

Ardavanis A, Tryfonopoulos D, Yiotis I, Gerasimidis G, Baziotis N, Rigatos G. Non-allergic nature of docetaxel-induced acute hypersensitivity reactions. Anticancer Drugs. 2004;15(6):581–5.PubMed

118.

Feldweg AM, Lee CW, Matulonis UA, Castells M. Rapid desensitization for hypersensitivity reactions to paclitaxel and docetaxel: a new standard protocol used in 77 successful treatments. Gynecol Oncol. 2005;96(3):824–9.PubMed

Titel: Diagnostic Tools for Hypersensitivity to Platinum Drugs and Taxanes: Skin Testing, Specific IgE, and Mast Cell/Basophil Mediators
verfasst von: Joana Caiado
Matthieu Picard
Publikationsdatum: 01.08.2014
Verlag: Springer US
Erschienen in: Current Allergy and Asthma Reports / Ausgabe 8/2014
Print ISSN: 1529-7322
Elektronische ISSN: 1534-6315
DOI: https://doi.org/10.1007/s11882-014-0451-7

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Diagnostic Tools for Hypersensitivity to Platinum Drugs and Taxanes: Skin Testing, Specific IgE, and Mast Cell/Basophil Mediators

Abstract

Neu im Fachgebiet HNO

Nur selten Nachblutungen nach Abszesstonsillektomie

Rezidivierender Peritonsillarabszess nach Oralsex

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

Kinder mit anhaltender Sinusitis profitieren häufig von Antibiotika

Update HNO

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2014

The Placebo Effect in Asthma

Allergic Reactions to Anisakis Found in Fish

Perioperative Anaphylaxis

Anaphylaxis as a Clinical Manifestation of Clonal Mast Cell Disorders

Desensitizations for Chemotherapy and Monoclonal Antibodies: Indications and Outcomes

Reply to “Role of Western Diet in Inflammatory Autoimmune Diseases” by Manzel et al. in Current Allergy and Asthma Reports (Volume 14, Issue 1, January 2014)

Neu im Fachgebiet HNO

Nur selten Nachblutungen nach Abszesstonsillektomie

Rezidivierender Peritonsillarabszess nach Oralsex

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

Kinder mit anhaltender Sinusitis profitieren häufig von Antibiotika

Update HNO